Trending

News

News

Celgene’s psoriasis drug meets phase 3 goals

Celgene has announced the results from phase 3 clinical trials of its psoriasis drug, which show the drug met its primary and secondary endpoints. Celgene International Sarl, a subsidiary of Celgene Corporation, has presented the results from the company’s first…

X

Celgene’s psoriasis drug meets phase 3 goals

https://pharmaphorum.com/news/celgenes_psoriasis_drug_meets_phase_3_goals/

India rejects Bayer’s cancer drug appeal

India’s ruling to allow generic versions of Bayer’s cancer drug, Nexavar, has been upheld by the country’s Intellectual Property Appellate Board. The Intellectual Property Appellate Board (IPAB) has decided to uphold a compulsory license allowing Natco Pharma to…

X

India rejects Bayer’s cancer drug appeal

https://pharmaphorum.com/news/india_rejects_bayers_cancer_drug_appeal/

UCB to license new Parkinson’s disease therapy from Biotie

UCB and Biotie amend their original 2010 agreement so that UCB now has the rights to Biotie’s new Parkinson’s disease therapy. UCB Pharma has announced it has licensed worldwide exclusive rights to Biotie Therapies’ tozadenant (SYN115), which is a…

X

UCB to license new Parkinson’s disease therapy from Biotie

https://pharmaphorum.com/news/ucb_to_license_new_parkinsons_disease_therapy_from_biotie/

Roche Chairman to step down in 2014

Franz B Humer has announced his decision to step down from his role as Roche’s Chairman after 16 years at the helm. Roche’s long-standing Chairman of the Board of Directors, Franz B Humer, will not stand for re-election in 2014. Franz has been…

X

Roche Chairman to step down in 2014

https://pharmaphorum.com/news/roche_chairman_to_step_down_in_2014/

Bayer Group sales increase by approximately 9%

Positive 2012 sales have been reported by the German pharmaceutical company, Bayer, which had sales increases in all subgroups. The Bayer Group has announced its full-year financial results for 2012, which turned out to be very successful for…

X

Bayer Group sales increase by approximately 9%

https://pharmaphorum.com/news/bayer_group_sales_increase_by_approximately_9/

Novartis’ acute gouty arthritis drug approved in Europe

Novartis’ acute gouty arthritis drug approved in Europe

Novartis has received European Commission approval for its acute gouty arthritis medicine

X

Novartis’ acute gouty arthritis drug approved in Europe

https://pharmaphorum.com/news/novartis_acute_gouty_arthritis_drug_approved_in_europe/

GSK’s ViiV Healthcare to increase HIV medicine access for children

Viiv Healthcare has entered into collaboration with the Medicines Patent Pool with the aim of increasing access to HIV medicines for children in 118 countries around the world. GlaxoSmithKline’s HIV / AIDS company, ViiV Healthcare, has announced a collaboration with the Medicines Patent Pool (MPP). The MPP is…

X

GSK’s ViiV Healthcare to increase HIV medicine access for children

https://pharmaphorum.com/news/gsks_viiv_healthcare_to_increase_hiv_medicine_access_for_children/

Rare Disease Day initiatives from Boehringer, Shire and Genzyme

Today is Rare Disease Day and many companies, both pharma and rare disease organisations, have announced their support for this awareness initiative. Today marks the sixth international Rare Disease Day, led by EURORDIS, to raise awareness for patients with rare…

X

Rare Disease Day initiatives from Boehringer, Shire and Genzyme

https://pharmaphorum.com/news/rare_disease_day_initiatives_from_boehringer_shire_and_genzyme-2/

PatientsLikeMe awarded $1.9m grant to create first open research platform

Patient organisation, PatientsLikeMe, has won a grant to create an open-participation research platform to help researchers develop better health outcome measures. The Robert Wood Johnson Foundation has awarded PatientsLikeMe with a US $1.9 million grant so it can create the world’s first…

X

PatientsLikeMe awarded $1.9m grant to create first open research platform

https://pharmaphorum.com/news/patientslikeme_awarded_1-9m_grant_to_create_first_open_research_platform/

«< 677 678 679 680 681 >»

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com